Hunan Fangsheng Pharm Co Ltd - Asset Resilience Ratio

Latest as of March 2026: 1.15%

Hunan Fangsheng Pharm Co Ltd (603998) has an Asset Resilience Ratio of 1.15% as of March 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Check Hunan Fangsheng Pharm Co Ltd (603998) strategic investment index to assess the company's strategic physical and investment asset allocation.

Liquid Assets

CN¥35.00 Million
≈ $5.12 Million USD Cash + Short-term Investments

Total Assets

CN¥3.06 Billion
≈ $447.12 Million USD All company assets

Resilience Assessment

Low
Financial Resilience Level

Asset Resilience Ratio Trend (2019–2023)

This chart shows how Hunan Fangsheng Pharm Co Ltd's Asset Resilience Ratio has changed over time. See 603998 equity financing ratio to measure how much of total assets are equity-financed.

Liquid Assets Composition Over Time

This chart breaks down Hunan Fangsheng Pharm Co Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see Hunan Fangsheng Pharm Co Ltd (603998) total market value.

Current Liquid Assets Breakdown

Component Amount % of Total Assets
Cash & Equivalents CN¥0.00 0%
Short-term Investments CN¥35.00 Million 1.15%
Total Liquid Assets CN¥35.00 Million 1.15%

Asset Resilience Insights

  • Limited Liquidity: Hunan Fangsheng Pharm Co Ltd maintains only 1.15% of assets in liquid form.
  • This low level may indicate efficient asset utilization but could pose risks during economic downturns.
  • The company has significant short-term investments, indicating active treasury management.

Hunan Fangsheng Pharm Co Ltd Industry Peers by Asset Resilience Ratio

Compare Hunan Fangsheng Pharm Co Ltd's asset resilience ratio with other companies in the same industry.

Company Industry Asset Resilience Ratio
Tonghua Dongbao Pharmaceutical Co Ltd
SHG:600867
Drug Manufacturers - Specialty & Generic 0.76%
Eris Lifesciences Limited
NSE:ERIS
Drug Manufacturers - Specialty & Generic 0.58%
Zhejiang Hisun Pharmaceutical Co Ltd
SHG:600267
Drug Manufacturers - Specialty & Generic 0.01%
Lotus Pharmaceutical Co Ltd
TW:1795
Drug Manufacturers - Specialty & Generic 0.49%
Tasly Pharmaceutical Group Co Ltd
SHG:600535
Drug Manufacturers - Specialty & Generic 11.69%
Changzhou Qianhong Biopharma Co Ltd
SHE:002550
Drug Manufacturers - Specialty & Generic 18.70%
Renhe Pharmacy Co Ltd
SHE:000650
Drug Manufacturers - Specialty & Generic 37.54%
Sun Pharma Advanced Research Company Limited
NSE:SPARC
Drug Manufacturers - Specialty & Generic 0.64%

Annual Asset Resilience Ratio for Hunan Fangsheng Pharm Co Ltd (2019–2023)

The table below shows the annual Asset Resilience Ratio data for Hunan Fangsheng Pharm Co Ltd.

Year Asset Resilience Ratio (%) Liquid Assets Total Assets Change
2023-12-31 0.66% CN¥20.33 Million
≈ $2.97 Million
CN¥3.08 Billion
≈ $450.85 Million
-0.72pp
2022-12-31 1.38% CN¥40.31 Million
≈ $5.90 Million
CN¥2.92 Billion
≈ $427.60 Million
+0.81pp
2021-12-31 0.57% CN¥15.42 Million
≈ $2.26 Million
CN¥2.70 Billion
≈ $395.75 Million
+0.56pp
2020-12-31 0.01% CN¥296.24K
≈ $43.35K
CN¥2.24 Billion
≈ $328.19 Million
0.00pp
2019-12-31 0.01% CN¥287.48K
≈ $42.07K
CN¥1.99 Billion
≈ $291.92 Million
--
pp = percentage points

About Hunan Fangsheng Pharm Co Ltd

SHG:603998 China Drug Manufacturers - Specialty & Generic
Market Cap
$600.75 Million
CN¥4.11 Billion CNY
Market Cap Rank
#11445 Global
#3280 in China
Share Price
CN¥9.35
Change (1 day)
+0.32%
52-Week Range
CN¥9.32 - CN¥13.01
All Time High
CN¥18.09
About

Hunan Fangsheng Pharmaceutical Co., Ltd. engages in research, develops, produces, and sells traditional Chinese medicine industry and chemical pharmaceutical products in China. The company offers pharmaceutical manufacturing; and provides cardiovascular and cerebrovascular drugs, skeletal muscle system drugs, orthopedic drugs, respiratory drugs, pediatric drugs, gynecological drugs, and anti-infe… Read more